RAFAEL HOLDINGS, INC. Stock-Based Compensation
RAFAEL HOLDINGS, INC. (RFL) reported Stock-Based Compensation of $1.16 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-04-30 was $172.00K, a 51.27% decline year-over-year.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-01-31 was $387.00K, a 22.91% decline year-over-year.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-10-31 was $598.00K, a 66.57% increase year-over-year.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-07-31 was $909.00K, a 108.49% increase year-over-year.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $2.12M, a 7.53% decline from fiscal 2024.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $2.30M, a 4.94% increase from fiscal 2023.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.19M.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was -$917.00K, a 113.82% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-04-30 | $172.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | $559.00K derived: sum of 2 quarters · filed 2026-06-11 | $1.16M 10-Q · filed 2026-06-11 | $2.07M derived: sum of 4 quarters · filed 2026-06-11 | |
| 2026-01-31 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | $985.00K 10-Q · filed 2026-03-16 | $1.89M derived: sum of 3 quarters · filed 2026-03-16 | $2.25M derived: sum of 4 quarters · filed 2026-06-11 | |
| 2025-10-31 | $598.00K 10-Q · filed 2025-12-12 | $1.51M derived: sum of 2 quarters · filed 2025-12-12 | $1.86M derived: sum of 3 quarters · filed 2026-06-11 | $2.36M derived: sum of 4 quarters · filed 2026-06-11 | |
| 2025-07-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $1.26M derived: sum of 2 quarters · filed 2026-06-11 | $1.76M derived: sum of 3 quarters · filed 2026-06-11 | $2.12M 10-K · filed 2025-10-29 | |
| 2025-04-30 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | $855.00K derived: sum of 2 quarters · filed 2026-06-11 | $1.21M 10-Q · filed 2026-06-11 | $1.65M derived: sum of 4 quarters · filed 2026-06-11 | |
| 2025-01-31 | $502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | $861.00K 10-Q · filed 2026-03-16 | $1.30M derived: sum of 3 quarters · filed 2026-03-16 | $1.79M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-10-31 | $359.00K 10-Q · filed 2025-12-12 | $795.00K derived: sum of 2 quarters · filed 2025-12-12 | $1.29M derived: sum of 3 quarters · filed 2025-12-12 | $2.01M derived: sum of 4 quarters · filed 2025-12-12 | |
| 2024-07-31 | $436.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $932.00K derived: sum of 2 quarters · filed 2025-10-29 | $1.65M derived: sum of 3 quarters · filed 2025-10-29 | $2.30M 10-K · filed 2025-10-29 | |
| 2024-04-30 | $496.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $1.21M derived: sum of 2 quarters · filed 2025-06-11 | $1.86M 10-Q · filed 2025-06-11 | $2.40M derived: sum of 4 quarters · filed 2025-06-11 | |
| 2024-01-31 | $715.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $1.36M 10-Q · filed 2025-03-14 | $1.90M derived: sum of 3 quarters · filed 2025-03-14 | $2.50M derived: sum of 4 quarters · filed 2025-03-14 | |
| 2023-10-31 | $649.00K 10-Q · filed 2024-12-11 | $1.19M derived: sum of 2 quarters · filed 2024-12-20 | $1.78M derived: sum of 3 quarters · filed 2024-12-20 | $1.66M derived: sum of 4 quarters · filed 2024-12-20 | |
| 2023-07-31 | $540.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $1.13M derived: sum of 2 quarters · filed 2024-12-20 | $1.01M derived: sum of 3 quarters · filed 2024-12-20 | $2.19M 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $468.00K derived: sum of 2 quarters · filed 2024-06-14 | $1.65M 10-Q · filed 2024-06-14 | $2.82M derived: sum of 4 quarters · filed 2024-06-14 | |
| 2023-01-31 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $1.06M 10-Q · filed 2024-03-14 | $2.23M derived: sum of 3 quarters · filed 2024-03-14 | $3.24M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-10-31 | $1.18M 10-Q · filed 2023-12-14 | $2.35M derived: sum of 2 quarters · filed 2023-12-14 | $3.36M derived: sum of 3 quarters · filed 2023-12-14 | -$7.59M derived: sum of 4 quarters · filed 2023-12-14 | |
| 2022-07-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | $2.18M derived: sum of 2 quarters · filed 2023-10-30 | -$8.77M derived: sum of 3 quarters · filed 2023-10-30 | -$917.00K 10-K · filed 2023-10-30 | |
| 2022-04-30 | $1.01M 10-Q · filed 2022-06-14 | -$9.94M derived: sum of 2 quarters · filed 2022-06-14 | -$2.09M 10-Q · filed 2023-06-13 | $3.52M derived: sum of 4 quarters · filed 2022-12-13 | |
| 2022-01-31 | -$10.95M 10-Q · filed 2022-03-17 | -$3.10M 10-Q · filed 2023-03-14 | $2.51M derived: sum of 3 quarters · filed 2022-12-13 | $2.82M derived: sum of 4 quarters · filed 2022-12-13 | |
| 2021-10-31 | $7.85M 10-Q · filed 2022-12-13 | $13.46M derived: sum of 2 quarters · filed 2022-12-13 | $13.77M derived: sum of 3 quarters · filed 2022-12-13 | $14.27M derived: sum of 4 quarters · filed 2022-12-13 | |
| 2021-07-31 | $5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $5.91M derived: sum of 2 quarters · filed 2022-10-31 | $6.42M derived: sum of 3 quarters · filed 2022-10-31 | $6.63M 10-K · filed 2022-10-31 | |
| 2021-04-30 | $304.00K 10-Q · filed 2022-06-14 | $700.00K 10-Q · filed 2021-06-14 | $809.00K derived: sum of 2 quarters · filed 2022-06-14 | $1.02M 10-Q · filed 2022-06-14 | $1.16M derived: sum of 4 quarters · filed 2022-06-14 |
| 2021-01-31 | $505.00K 10-Q · filed 2022-03-17 | $719.00K 10-Q · filed 2022-03-17 | $857.00K derived: sum of 3 quarters · filed 2022-03-17 | $992.00K derived: sum of 4 quarters · filed 2022-03-17 | |
| 2020-10-31 | $214.00K 10-Q/A · filed 2022-02-28 | $352.00K derived: sum of 2 quarters · filed 2022-02-28 | $487.00K derived: sum of 3 quarters · filed 2022-02-28 | $804.00K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-07-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | $273.00K derived: sum of 2 quarters · filed 2021-10-18 | $590.00K derived: sum of 3 quarters · filed 2021-10-18 | $684.00K 10-K · filed 2021-10-18 | |
| 2020-04-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $452.00K derived: sum of 2 quarters · filed 2021-06-14 | $546.00K 10-Q · filed 2021-06-14 | ||
| 2020-01-31 | $317.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | $411.00K 10-Q · filed 2021-03-17 | |||
| 2019-10-31 | $94.00K 10-Q · filed 2020-12-15 | ||||
| 2018-07-31 | -$565.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15 | -$555.00K derived: sum of 2 quarters · filed 2018-10-15 | $51.00K 10-K · filed 2018-10-15 | ||
| 2018-04-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-06-11 | $616.00K 10-Q · filed 2018-06-11 | |||
| 2018-01-31 | $606.00K 10-Q · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |